Key facts
- This page summarizes Scott A. Kelly's Form 4 filing for CytoDyn Inc. (CYDY).
- 2 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 30 Nov 2022, 19:33.
Scott A. Kelly - 28 Nov 2022 Form 4 Insider Report for CytoDyn Inc. (CYDY)
- SEC form
- 4
- Accepted by SEC
- 30 Nov 2022, 19:33:01 UTC
- Prior SEC filing
- 17 Nov 2022
- Source filing
- View source filing
- Reporting owner signature
- /s/ Antonio Migliarese, Attorney-In-Fact
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Scott A. Kelly filed Form 4 for CytoDyn Inc. (CYDY) on 30 Nov 2022.
Change
- Previous filing in this sequence was filed on 17 Nov 2022.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
CYDY
transaction
Common Stock
Award
- Transaction value
- $0
- Shares
- +16,927
- Change %
- +0.78%
- Price
- $0.000000
- Shares after
- 2,184,037
- Date
- 30 Nov 2022
- Ownership
- Direct
- Footnotes
- F1
CYDY
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 782,408
- Date
- 28 Nov 2022
- Ownership
- By Spouse
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
CYDY
transaction
Derivative
Non-qualified stock option (right to buy)
Award
- Transaction value
- $0
- Shares
- +2,315,439
- Change %
- Price
- $0.000000
- Shares after
- 2,315,439
- Date
- 28 Nov 2022
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 2,315,439
- Exercise price
- $0.3500
- Footnotes
- F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
Represents awards of fully vested shares under the issuer's 2012 Equity Incentive Plan approved by its Compensation Committee of the Board of Directors with a value on the respective date of grant equal to reduction in reporting person's cash salary.
Footnote F2
241,190 shares vested on November 28, 2022; the balance will vest on a monthly basis as follows (i) 48,238 shares at the conclusion of each month of Continuous Service (as the term is defined in the Issuer's 2012 Equity Incentive Plan, as amended), from November 2022 through February 2025, and (ii) 48,239 shares at the conclusion of each month of Continuous Service, from March 2025 through May 2026.